Safety Study of Abatacept in Rheumatoid Arthritis Participants
NCT ID: NCT03696173
Last Updated: 2018-10-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
5800 participants
OBSERVATIONAL
2015-12-17
2018-06-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)
NCT01088321
A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents
NCT03670667
Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)
NCT01088360
Safety Study of Abatacept to Treat Rheumatoid Arthritis
NCT01247766
Phase IIIB Subcutaneous Abatacept Monotherapy Study
NCT00547521
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participants taking abatacept
Non-Interventional
Non-Interventional
Participants taking abatacept with methotrexate
Non-Interventional
Non-Interventional
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Non-Interventional
Non-Interventional
Non-Interventional
Non-Interventional
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient has at least two diagnoses for RA in the patient's history prior to and including the entry date or within the 180 days after the entry date
* Patient is aged 18 years or older on the entry date
* Patient was enrolled in the database for at least 180 days before the entry date
Exclusion Criteria
* Patients who receive abatacept and another biologic simultaneously
* Patients who have an outcome diagnosis in the baseline period will be excluded from the cohort analyses for that outcome
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Bristol-Myers Squibb
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Princeton, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
BMS Clinical Trial Information
Investigator Inquiry Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IM101-605
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.